{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:50:35Z","timestamp":1758819035034,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Center for Clinical Medical Research on Diseases Project","award":["2020ZKMB02"],"award-info":[{"award-number":["2020ZKMB02"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00432-021-03587-6","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T14:38:42Z","timestamp":1618497522000},"page":"3441-3445","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical features and treatment outcomes of 14 patients with hepatosplenic \u03b3 \u03b4 T-cell lymphoma"],"prefix":"10.1007","volume":"147","author":[{"given":"Qian","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yibin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yishan","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengming","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caixia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1824-5247","authenticated-orcid":false,"given":"Haiwen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"key":"3587_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/08998280.2018.1509592","volume":"32","author":"S Amin","year":"2019","unstructured":"Amin S, Findeis SK, Whiteley A, Krause JR (2019) An unusual presentation of an uncommon lymphoma, hepatosplenic T-cell lymphoma. Baylor Univ Med Center Proc 32:129\u2013130. https:\/\/doi.org\/10.1080\/08998280.2018.1509592","journal-title":"Baylor Univ Med Center Proc"},{"key":"3587_CR2","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1182\/blood-2003-05-1675","volume":"102","author":"K Belhadj","year":"2003","unstructured":"Belhadj K (2003) Hepatosplenic T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 102:4261\u20134269. https:\/\/doi.org\/10.1182\/blood-2003-05-1675","journal-title":"Blood"},{"key":"3587_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.09.013","author":"L Bojanini","year":"2020","unstructured":"Bojanini L, Jiang L, Tun AJ et al (2020) Outcomes of hepatosplenic T-cell lymphoma: the mayo clinic experience. Clin Lymphoma Myeloma Leuk. https:\/\/doi.org\/10.1016\/j.clml.2020.09.013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3587_CR4","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.3109\/10428194.2014.889821","volume":"55","author":"M Calvaruso","year":"2014","unstructured":"Calvaruso M, Gulino A, Buffa S et al (2014) Challenges and new prospects in hepatosplenic \u03b3\u03b4 T-cell lymphoma. Leuk Lymphoma 55:2457\u20132465. https:\/\/doi.org\/10.3109\/10428194.2014.889821","journal-title":"Leuk Lymphoma"},{"key":"3587_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02632-y","author":"S Dhawan","year":"2019","unstructured":"Dhawan S, Gordon A, Singh S et al (2019) Gamma-delta hepato-splenic T-cell lymphoma: a pathological illustration. Int J Hematol. https:\/\/doi.org\/10.1007\/s12185-019-02632-y","journal-title":"Int J Hematol"},{"key":"3587_CR6","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/annonc\/mdn751","volume":"20","author":"GS Falchook","year":"2009","unstructured":"Falchook GS, Vega F, Dang NH et al (2009) Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol 20:1080\u20131085. https:\/\/doi.org\/10.1093\/annonc\/mdn751","journal-title":"Ann Oncol"},{"key":"3587_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/ajh.25674","volume":"95","author":"FM Foss","year":"2020","unstructured":"Foss FM, Horwitz SM, Civallero M et al (2020) Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. Am J Hematol 95:151\u2013155. https:\/\/doi.org\/10.1002\/ajh.25674","journal-title":"Am J Hematol"},{"key":"3587_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3960\/jslrt.20003","volume":"60","author":"N Iwaki","year":"2020","unstructured":"Iwaki N, Mochizuki K, Ozaki J et al (2020) A case of hepatosplenic T-cell lymphoma successfully treated by HLA haploidentical stem cell transplantation. JCEH 60:55\u201359. https:\/\/doi.org\/10.3960\/jslrt.20003","journal-title":"JCEH"},{"key":"3587_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cancergen.2018.06.003","volume":"228\u2013229","author":"H Jain","year":"2018","unstructured":"Jain H, Shetty D, Jain H et al (2018) A rare case of hepatosplenic \u03b3\u03b4 T-cell lymphoma expressing CD19 with ring chromosome 7 and trisomy 8. Cancer Genet 228\u2013229:17\u201320. https:\/\/doi.org\/10.1016\/j.cancergen.2018.06.003","journal-title":"Cancer Genet"},{"key":"3587_CR10","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1093\/annonc\/mdq635","volume":"22","author":"HC Kluin-Nelemans","year":"2011","unstructured":"Kluin-Nelemans HC, van Marwijk KM, Lugtenburg PJ et al (2011) Intensified alemtuzumab\u2013CHOP therapy for peripheral T-cell lymphoma. Ann Oncol 22:1595\u20131600. https:\/\/doi.org\/10.1093\/annonc\/mdq635","journal-title":"Ann Oncol"},{"key":"3587_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1200\/JOP.18.00594","volume":"15","author":"M Krishnan","year":"2019","unstructured":"Krishnan M, Lunning M (2019) Hepatosplenic \u03b3-\u03b4 T-Cell Lymphoma: Who Is on Your Speed Dial? JOP 15:307\u2013312. https:\/\/doi.org\/10.1200\/JOP.18.00594","journal-title":"JOP"},{"key":"3587_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.lrr.2015.12.001","volume":"5","author":"H Matsushita","year":"2016","unstructured":"Matsushita H, Ohmachi K, Kojima M et al (2016) Four hepatosplenic T-cell lymphoma cases of Japanese patients. Leuk Res Rep 5:3\u20136. https:\/\/doi.org\/10.1016\/j.lrr.2015.12.001","journal-title":"Leuk Res Rep"},{"key":"3587_CR13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1158\/2159-8290.CD-16-0330","volume":"7","author":"M McKinney","year":"2017","unstructured":"McKinney M, Moffitt AB, Gaulard P et al (2017) The genetic basis of hepatosplenic T-cell lymphoma. Cancer Discov 7:369\u2013379. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0330","journal-title":"Cancer Discov"},{"key":"3587_CR14","doi-asserted-by":"publisher","first-page":"e12941","DOI":"10.1097\/MD.0000000000012941","volume":"97","author":"H Pan","year":"2018","unstructured":"Pan H, Huang J, Li J-N et al (2018) Successful second allogeneic stem-cell transplantation from the same sibling donor for a patient with recurrent hepatosplenic gamma-delta (\u03b3\/\u03b4) T-cell lymphoma: a case report. Medicine 97:e12941. https:\/\/doi.org\/10.1097\/MD.0000000000012941","journal-title":"Medicine"},{"key":"3587_CR15","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1182\/blood.2019004118","volume":"136","author":"B Pro","year":"2020","unstructured":"Pro B, Allen P, Behdad A (2020) Hepatosplenic T-cell lymphoma: a rare but challenging entity. Blood 136:2018\u20132026. https:\/\/doi.org\/10.1182\/blood.2019004118","journal-title":"Blood"},{"key":"3587_CR16","doi-asserted-by":"publisher","first-page":"7174","DOI":"10.1158\/1078-0432.CCR-06-1275","volume":"12","author":"SJ Rodig","year":"2006","unstructured":"Rodig SJ, Abramson JS, Pinkus GS et al (2006) Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 12:7174\u20137179. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1275","journal-title":"Clin Cancer Res"},{"key":"3587_CR17","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.clml.2013.03.011","volume":"13","author":"K Visnyei","year":"2013","unstructured":"Visnyei K, Grossbard ML, Shapira I (2013) Hepatosplenic \u03b3\u03b4 T-cell lymphoma: an Overview. Clin Lymphoma Myeloma Leuk 13:360\u2013369. https:\/\/doi.org\/10.1016\/j.clml.2013.03.011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3587_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.clml.2012.09.002","volume":"13","author":"MH Voss","year":"2013","unstructured":"Voss MH, Lunning MA, Maragulia JC et al (2013) Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic t-cell lymphoma: a single institution experience. Clin Lymphoma Myeloma Leuk 13:8\u201314. https:\/\/doi.org\/10.1016\/j.clml.2012.09.002","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3587_CR19","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/sj.leu.2401784","volume":"14","author":"E Weidmann","year":"2000","unstructured":"Weidmann E (2000) Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia 14:991\u2013997. https:\/\/doi.org\/10.1038\/sj.leu.2401784","journal-title":"Leukemia"},{"key":"3587_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.anndiagpath.2016.10.005","volume":"26","author":"M Yabe","year":"2017","unstructured":"Yabe M, Medeiros LJ, Daneshbod Y et al (2017) Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor\u2013\u03b1 inhibitor therapy and literature review. Ann Diagn Pathol 26:16\u201322. https:\/\/doi.org\/10.1016\/j.anndiagpath.2016.10.005","journal-title":"Ann Diagn Pathol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03587-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03587-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03587-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T17:12:22Z","timestamp":1633021942000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03587-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,15]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["3587"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03587-6","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"type":"print","value":"0171-5216"},{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2021,4,15]]},"assertion":[{"value":"28 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics committee of the First Affiliated Hospital of Soochow University. We have obtained written and signed consent to publish this paper from these patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}